IN2014CN02703A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02703A IN2014CN02703A IN2703CHN2014A IN2014CN02703A IN 2014CN02703 A IN2014CN02703 A IN 2014CN02703A IN 2703CHN2014 A IN2703CHN2014 A IN 2703CHN2014A IN 2014CN02703 A IN2014CN02703 A IN 2014CN02703A
- Authority
- IN
- India
- Prior art keywords
- pertuzumab
- her2 positive
- treating
- cancer
- trastuzumab
- Prior art date
Links
- 229960002087 pertuzumab Drugs 0.000 abstract 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 5
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 229960000575 trastuzumab Drugs 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000001990 intravenous administration Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 206010048610 Cardiotoxicity Diseases 0.000 abstract 1
- 201000001342 Fallopian tube cancer Diseases 0.000 abstract 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 abstract 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 abstract 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 231100000259 cardiotoxicity Toxicity 0.000 abstract 1
- 230000007681 cardiovascular toxicity Effects 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 abstract 1
- 229960002066 vinorelbine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Packages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547535P | 2011-10-14 | 2011-10-14 | |
| US201161567015P | 2011-12-05 | 2011-12-05 | |
| US201261657669P | 2012-06-08 | 2012-06-08 | |
| US201261682037P | 2012-08-10 | 2012-08-10 | |
| US201261694584P | 2012-08-29 | 2012-08-29 | |
| PCT/US2012/059683 WO2013055874A2 (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02703A true IN2014CN02703A (ru) | 2015-07-03 |
Family
ID=47073543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2703CHN2014 IN2014CN02703A (ru) | 2011-10-14 | 2012-10-11 |
Country Status (29)
| Country | Link |
|---|---|
| US (9) | US20130095172A1 (ru) |
| EP (6) | EP4403228A3 (ru) |
| JP (8) | JP2014530235A (ru) |
| KR (5) | KR102679155B1 (ru) |
| CN (8) | CN104334189A (ru) |
| AU (4) | AU2012322797B2 (ru) |
| BR (1) | BR112014007521A8 (ru) |
| CL (1) | CL2014000889A1 (ru) |
| DK (1) | DK2766040T3 (ru) |
| EA (1) | EA034390B1 (ru) |
| ES (1) | ES2736005T3 (ru) |
| HK (1) | HK1202242A1 (ru) |
| HR (1) | HRP20191247T1 (ru) |
| HU (1) | HUE044352T2 (ru) |
| IL (4) | IL309917A (ru) |
| IN (1) | IN2014CN02703A (ru) |
| LT (1) | LT2766040T (ru) |
| MX (2) | MX2014004021A (ru) |
| MY (2) | MY172326A (ru) |
| PE (1) | PE20142363A1 (ru) |
| PH (1) | PH12019500519A1 (ru) |
| PL (1) | PL2766040T3 (ru) |
| PT (1) | PT2766040T (ru) |
| RS (1) | RS58944B1 (ru) |
| SG (3) | SG10202110077QA (ru) |
| SI (1) | SI2766040T1 (ru) |
| UA (2) | UA123092C2 (ru) |
| WO (1) | WO2013055874A2 (ru) |
| ZA (1) | ZA201401259B (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| CN103432580A (zh) | 2007-03-02 | 2013-12-11 | 健泰科生物技术公司 | 基于低her3表达预测对her二聚化抑制剂的响应 |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010062171A2 (en) | 2008-11-03 | 2010-06-03 | Syntarga B.V. | Novel cc-1065 analogs and their conjugates |
| DK3056203T3 (da) | 2010-04-21 | 2018-01-29 | Syntarga Bv | Konjugater af cc-1065-analoger og bifunktionelle linkere. |
| SI2766040T1 (sl) | 2011-10-14 | 2019-08-30 | F. Hoffmann-La Roche Ag | Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| CA3071678A1 (en) | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
| EP3010501B1 (en) * | 2013-06-19 | 2021-11-03 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| KR102447878B1 (ko) | 2013-12-17 | 2022-09-26 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| CN104726462A (zh) * | 2013-12-20 | 2015-06-24 | 北京天广实生物技术股份有限公司 | 抗her2人源化抗体mil41、其制备方法及用途 |
| CN105899237B (zh) * | 2014-01-10 | 2019-09-03 | 斯索恩生物制药有限公司 | 用于治疗子宫内膜癌的倍癌霉素adc |
| KR102344354B1 (ko) | 2014-01-10 | 2021-12-28 | 비온디스 비.브이. | 향상된 생체내 항종양 활성을 나타내는 듀오카르마이신 adc |
| TR201810856T4 (tr) | 2014-01-10 | 2018-08-27 | Synthon Biopharmaceuticals Bv | CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul. |
| WO2016094341A1 (en) * | 2014-12-08 | 2016-06-16 | Synta Pharmaceuticals Corp. | Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer |
| WO2016196523A1 (en) * | 2015-05-29 | 2016-12-08 | Expression Pathology, Inc. | Quantifying her2 protein for optimal cancer therapy |
| CN107771076A (zh) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| MA45324A (fr) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
| CN110505880A (zh) * | 2016-11-04 | 2019-11-26 | 基因泰克公司 | Her2阳性乳腺癌的治疗 |
| TW201827077A (zh) * | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
| MA56006A (fr) * | 2017-01-17 | 2022-05-04 | Hoffmann La Roche | Formulations sous-cutanées d'anticorps her2 |
| CN116531511A (zh) * | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| KR102267593B1 (ko) * | 2018-10-19 | 2021-06-21 | 주식회사 프로티나 | Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법 |
| WO2020240417A1 (en) * | 2019-05-27 | 2020-12-03 | Tolmar International Limited | Leuprolide acetate compositions and methods of using the same to treat breast cancer |
| KR20220027969A (ko) | 2019-06-28 | 2022-03-08 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 프리리포솜 아나마이신 동결건조물의 제조 |
| CN114728101B (zh) * | 2019-06-28 | 2023-07-14 | 德州大学系统董事会 | 重构脂质体安那霉素的方法 |
| US20230175069A1 (en) * | 2020-04-29 | 2023-06-08 | University Of Pittsburgh-Of The Commonweal Th System Of Higher Education | Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment |
| CN111710425A (zh) * | 2020-06-19 | 2020-09-25 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置 |
| KR20240119103A (ko) * | 2021-12-07 | 2024-08-06 | 아이오 테라퓨틱스, 인크. | Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU3934085A (en) | 1984-01-30 | 1985-08-09 | Icrf Patents Ltd. | Improvements relating to growth factors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| ES2106033T3 (es) | 1989-05-19 | 1997-11-01 | Genentech Inc | Dominio extracelular de her2. |
| JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量 |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| SI2275119T1 (sl) | 1995-07-27 | 2013-12-31 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| SI0950067T1 (sl) | 1996-11-27 | 2007-12-31 | Genentech Inc | Afinitetno čiščenje polipeptida na proteinskemA matriksu |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| PT1064027E (pt) | 1998-03-27 | 2008-09-29 | Genentech Inc | Sinergismo de ligando de apo-2 e anticorpo anti-her-2 |
| DK1308456T3 (da) | 1998-05-06 | 2007-12-27 | Genentech Inc | Antistofoprensning ved ionbytterkromatografi |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2374085C (en) | 1999-05-14 | 2015-12-29 | Genentech, Inc. | Tumour treatment with anti-erbb2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| ES2282120T3 (es) | 1999-06-25 | 2007-10-16 | Genentech, Inc. | Tratamiento del cancer de prostata con anticuerpos anti-erbb2. |
| IL146954A0 (en) | 1999-06-25 | 2002-08-14 | Genentech Inc | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| CN101711868A (zh) | 2000-05-19 | 2010-05-26 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| ES2401428T3 (es) | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
| EP2263691B1 (en) | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| AU2003265994B2 (en) | 2002-09-11 | 2010-04-01 | Genentech, Inc. | Protein purification |
| WO2004030621A2 (en) * | 2002-09-30 | 2004-04-15 | The Trustees Of Boston University | Method of treating cancer using adenosine and its analogs |
| JP2006516117A (ja) | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療 |
| EP1648940B1 (en) | 2003-07-28 | 2016-04-27 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| AU2005232657B2 (en) | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
| EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| US20050280299A1 (en) | 2004-06-18 | 2005-12-22 | Alfmeier Corporation | Mounting adaptor for seat assembly, and seat assembly having mounting adaptor |
| SI1771482T1 (sl) | 2004-07-22 | 2014-12-31 | Genentech, Inc. | Sestavek HER2 protitelesa |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2007114111A (ru) * | 2004-11-04 | 2008-12-10 | Пфайзер Продактс Инк. (Us) | Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы |
| CN101115849A (zh) | 2004-12-07 | 2008-01-30 | 健泰科生物技术公司 | 选择her抑制剂疗法的患者 |
| US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
| CA3054535A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| MY157955A (en) | 2005-07-06 | 2016-08-30 | Hoffmann La Roche | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| AU2007259171A1 (en) | 2006-06-05 | 2007-12-21 | F. Hoffmann-La Roche, Ag | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| KR101155847B1 (ko) | 2006-06-14 | 2012-06-20 | 도요타 지도샤（주） | 배기 가스 정화용 촉매 |
| US20080050385A1 (en) | 2006-08-21 | 2008-02-28 | Thomas Friess | Tumor therapy with an anti-vegf antibody |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| CN103432580A (zh) * | 2007-03-02 | 2013-12-11 | 健泰科生物技术公司 | 基于低her3表达预测对her二聚化抑制剂的响应 |
| MX2009012838A (es) | 2007-06-06 | 2009-12-11 | Hoffmann La Roche | Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo. |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| MX338504B (es) | 2007-09-12 | 2016-04-20 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. |
| WO2009051815A1 (en) * | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| SI2215117T2 (en) | 2007-10-30 | 2018-04-30 | Genentech, Inc. | Purification of the antibody by cation exchange chromatography |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20090203015A1 (en) * | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
| EP2260056A1 (en) | 2008-03-06 | 2010-12-15 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| EP3692988A3 (en) | 2008-03-18 | 2020-10-14 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use |
| BRPI0812682A2 (pt) * | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| AU2009316409A1 (en) * | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TW201129380A (en) * | 2009-12-04 | 2011-09-01 | Genentech Inc | Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1 |
| SI2766040T1 (sl) | 2011-10-14 | 2019-08-30 | F. Hoffmann-La Roche Ag | Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke |
-
2012
- 2012-10-11 SI SI201231637T patent/SI2766040T1/sl unknown
- 2012-10-11 PL PL12778010T patent/PL2766040T3/pl unknown
- 2012-10-11 CN CN201280061896.3A patent/CN104334189A/zh active Pending
- 2012-10-11 UA UAA201709999A patent/UA123092C2/uk unknown
- 2012-10-11 ES ES12778010T patent/ES2736005T3/es active Active
- 2012-10-11 KR KR1020237005562A patent/KR102679155B1/ko active IP Right Grant
- 2012-10-11 US US13/649,591 patent/US20130095172A1/en not_active Abandoned
- 2012-10-11 LT LTEP12778010.4T patent/LT2766040T/lt unknown
- 2012-10-11 PT PT12778010T patent/PT2766040T/pt unknown
- 2012-10-11 SG SG10202110077Q patent/SG10202110077QA/en unknown
- 2012-10-11 CN CN202310701159.5A patent/CN116808199A/zh active Pending
- 2012-10-11 MX MX2014004021A patent/MX2014004021A/es active IP Right Grant
- 2012-10-11 EP EP24174637.9A patent/EP4403228A3/en active Pending
- 2012-10-11 MY MYPI2014001060A patent/MY172326A/en unknown
- 2012-10-11 SG SG11201401432XA patent/SG11201401432XA/en unknown
- 2012-10-11 AU AU2012322797A patent/AU2012322797B2/en active Active
- 2012-10-11 KR KR1020237015216A patent/KR20230073340A/ko not_active Application Discontinuation
- 2012-10-11 HU HUE12778010 patent/HUE044352T2/hu unknown
- 2012-10-11 PE PE2014000507A patent/PE20142363A1/es active IP Right Grant
- 2012-10-11 EP EP19165341.9A patent/EP3598981A3/en not_active Withdrawn
- 2012-10-11 CN CN201811518146.XA patent/CN109908341B/zh active Active
- 2012-10-11 KR KR1020247021013A patent/KR20240109285A/ko active Application Filing
- 2012-10-11 EP EP23172794.2A patent/EP4234033A3/en active Pending
- 2012-10-11 DK DK12778010.4T patent/DK2766040T3/da active
- 2012-10-11 IN IN2703CHN2014 patent/IN2014CN02703A/en unknown
- 2012-10-11 EP EP23172847.8A patent/EP4241849B1/en active Active
- 2012-10-11 CN CN202310108240.2A patent/CN116271013A/zh active Pending
- 2012-10-11 JP JP2014535859A patent/JP2014530235A/ja not_active Withdrawn
- 2012-10-11 SG SG10201606756PA patent/SG10201606756PA/en unknown
- 2012-10-11 EP EP23172860.1A patent/EP4234034A3/en active Pending
- 2012-10-11 RS RS20190845A patent/RS58944B1/sr unknown
- 2012-10-11 KR KR1020147009738A patent/KR102099991B1/ko active IP Right Grant
- 2012-10-11 CN CN202310820523.XA patent/CN117018187A/zh active Pending
- 2012-10-11 EA EA201490779A patent/EA034390B1/ru active Protection Beyond IP Right Term
- 2012-10-11 WO PCT/US2012/059683 patent/WO2013055874A2/en active Application Filing
- 2012-10-11 CN CN202210486683.0A patent/CN114984205A/zh active Pending
- 2012-10-11 IL IL309917A patent/IL309917A/en unknown
- 2012-10-11 IL IL301603A patent/IL301603A/en unknown
- 2012-10-11 KR KR1020177004681A patent/KR102502545B1/ko active IP Right Grant
- 2012-10-11 EP EP12778010.4A patent/EP2766040B1/en not_active Revoked
- 2012-10-11 BR BR112014007521A patent/BR112014007521A8/pt not_active Application Discontinuation
- 2012-10-11 CN CN202310135044.4A patent/CN116236569A/zh active Pending
- 2012-10-11 CN CN202310064889.9A patent/CN116271011B/zh active Active
- 2012-10-11 MY MYPI2019003795A patent/MY194408A/en unknown
- 2012-11-10 UA UAA201405091A patent/UA116095C2/uk unknown
-
2014
- 2014-02-19 ZA ZA2014/01259A patent/ZA201401259B/en unknown
- 2014-03-06 IL IL231350A patent/IL231350B2/en unknown
- 2014-04-03 MX MX2019009153A patent/MX2019009153A/es unknown
- 2014-04-09 CL CL2014000889A patent/CL2014000889A1/es unknown
-
2015
- 2015-03-17 HK HK15102729.7A patent/HK1202242A1/xx unknown
-
2016
- 2016-03-02 US US15/058,520 patent/US20160175438A1/en not_active Abandoned
- 2016-07-15 AU AU2016204962A patent/AU2016204962B2/en active Active
-
2017
- 2017-06-28 JP JP2017125883A patent/JP2017222663A/ja not_active Withdrawn
-
2018
- 2018-06-05 AU AU2018203970A patent/AU2018203970B2/en active Active
- 2018-09-06 US US16/123,809 patent/US20190117769A1/en not_active Abandoned
-
2019
- 2019-03-11 PH PH12019500519A patent/PH12019500519A1/en unknown
- 2019-07-11 HR HRP20191247TT patent/HRP20191247T1/hr unknown
- 2019-10-02 JP JP2019182187A patent/JP6646785B1/ja active Active
- 2019-11-04 AU AU2019261666A patent/AU2019261666B2/en active Active
-
2020
- 2020-01-10 JP JP2020002531A patent/JP2020090507A/ja not_active Withdrawn
- 2020-02-20 US US16/796,163 patent/US20200206348A1/en not_active Abandoned
- 2020-08-13 US US16/992,966 patent/US20210015919A1/en not_active Abandoned
- 2020-08-17 US US16/994,950 patent/US20200376120A1/en not_active Abandoned
-
2021
- 2021-10-03 IL IL286921A patent/IL286921A/en unknown
-
2022
- 2022-01-06 JP JP2022000876A patent/JP2022062010A/ja not_active Withdrawn
- 2022-03-28 US US17/656,732 patent/US20220362379A1/en not_active Abandoned
-
2023
- 2023-04-28 US US18/309,452 patent/US20230277663A1/en active Pending
- 2023-04-28 US US18/309,488 patent/US20230277664A1/en not_active Abandoned
- 2023-05-01 JP JP2023075391A patent/JP7352760B2/ja active Active
- 2023-05-01 JP JP2023075388A patent/JP7303957B1/ja active Active
- 2023-09-15 JP JP2023150231A patent/JP2024009803A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500519A1 (en) | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| NZ602084A (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| NZ711038A (en) | Tricyclic inhibitors of atr | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| MX368228B (es) | Anticuerpos que se unen específicamente a her2. | |
| NZ707090A (en) | Synthetic lethality and the treatment of cancer | |
| SG194735A1 (en) | Compositions and methods for treating cancer | |
| PH12016501554A1 (en) | Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug | |
| MX2016006894A (es) | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. | |
| EA201991164A1 (ru) | Применение ингибитора димеризации her2 пертузумаба в качестве промышленного изделия и промышленное изделие, включающее ингибитор димеризации her2 пертузумаб | |
| MX2017009733A (es) | Uso de una mezcla de polímeros de glucosa modificados para reducir la metástasis tumoral. | |
| WO2015069656A8 (en) | Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients | |
| RU2012115039A (ru) | Способ лечения хронического эндометрита | |
| UA105159C2 (ru) | Способ лечения рецидива варикозной болезни нижних конечностей | |
| MD482Z (ru) | Метод профилактики осложнений радиотерапии органов малого таза | |
| UA68337U (ru) | Способ комплексного лечения рака ободочной кишки | |
| WO2011085288A3 (en) | Method of administration and treatment | |
| MX2015016893A (es) | Combinacion de ro5503781 y capecitabina para la terapia para el cancer. | |
| UA98731C2 (ru) | Применение n-стеароилетаноламина в качестве средства в комплексной терапии и профилактике расстройств мужской половой системы | |
| MD854Y (ru) | Метод лечения местно-распространенного рака шейки матки стадии II-III | |
| UA40876U (ru) | Способ лечения травматического повреждения почки |